GRAIL, Inc. (GRAL) company profile
Close on Nov 17, 2026Market cap $4.73BP/E –Yield –
About Grail
Services-Medical Laboratories, SIC 8071
The company is a commercial-stage healthcare organization focused on multi-cancer early detection at population scale. Its core offering is Galleri, a multi-cancer early detection screening blood test designed to screen for over 50 cancer types by analyzing cell-free DNA methylation patterns and predicting the cancer signal of origin. Beyond asymptomatic population screening, the business offers a research-use-only targeted methylation platform with customizable classifiers for biopharmaceutical and oncology therapeutics partners, supporting precision oncology applications such as biomarker discovery, prognosis, and recurrence monitoring. Its customer base includes healthcare systems, self-insured employers, digital health platforms, health insurers, life insurance providers, and biopharmaceutical developers.
The company processes commercial and clinical tests through an accredited high-capacity laboratory capable of processing up to one million tests per year, having processed over 800,000 tests across clinical and commercial settings. Operating primarily in the United States, it has initiated international expansion into select markets such as Canada and Israel through distributor partnerships, with plans to enter South Korea and potential future deployment with the National Health Service in the United Kingdom. The provided text does not state the location of the company's headquarters.
Summary of the business section of Grail's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GRAIL, Inc.
- Founded
- 2016
- Headquarters
- Sunnyvale, CA
- Address
- 250 S. Mathilda Avenue, Suite 100 94086
- Phone
- (833) 694-2553
- Website
- grail.com
- Employees
- 910, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- GRAL
- Exchange
- Nasdaq
- IPO date
- Jun 12, 2024
- Shares outstanding
- 45M, Aug 3, 2026
- Public float
- $1.90B, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1699031
- CUSIP
- 384747101
- ISIN
- US3847471014
- FIGI
- BBG01N6CGW43
- Share class FIGI
- BBG01N6CGX05
- LEI
- 2549009XSNESW3VE8024
- EIN
- 86-3673636
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joshua J. Ofman | Chief Executive Officer, Director | 342,271 |
| Robert P. Ragusa | Chief Executive Officer, Director | 518,582 |
| Aaron Freidin | Chief Financial Officer | 222,364 |
| Andrew John Partridge | Chief Growth Officer | 155,865 |
| William J. Chase | Director | 43,131 |
| Steven Mizell | Director | 42,978 |
| Gregory L. Summe | Director | 45,909 |
| Sarah Krevans | Director | 42,628 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Robert Ragusa Chief Executive Officer | $785.00K | – | $6.48M | $778.09K | $53.31K | $8.09M | +6% |
| Aaron Freidin Chief Financial Officer | $560.00K | $250.00K | $2.00M | $321.94K | $3.00K | $3.13M | -15% |
| Joshua Ofman President | $655.00K | – | $3.19M | $376.56K | $92.43K | $4.32M | -26% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 910 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 12, 2024 | Name change | Name changed from GRAIL, LLC to GRAIL, Inc. |
| May 6, 2024 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |
See a number that looks wrong?